PYC Therapeutics Limited (PYC.AX)
AUD 1.23
(-1.21%)
AUD 1.23
(-1.21%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -38.85 Million AUD | 0.78% |
| 2023 | -39.16 Million AUD | -29.65% |
| 2022 | -30.2 Million AUD | -38.36% |
| 2021 | -21.83 Million AUD | -125.04% |
| 2020 | -9.7 Million AUD | -36.61% |
| 2019 | -7.1 Million AUD | 27.29% |
| 2018 | -9.76 Million AUD | -129.75% |
| 2017 | -4.25 Million AUD | 28.56% |
| 2016 | -5.95 Million AUD | -18.23% |
| 2015 | -5.03 Million AUD | 2.0% |
| 2014 | -5.13 Million AUD | 15.86% |
| 2013 | -6.1 Million AUD | -50.13% |
| 2012 | -4.06 Million AUD | -9.37% |
| 2011 | -3.71 Million AUD | 20.3% |
| 2010 | -4.66 Million AUD | -25.98% |
| 2009 | -3.7 Million AUD | 33.57% |
| 2008 | -5.57 Million AUD | -18.7% |
| 2007 | -4.69 Million AUD | -15.18% |
| 2006 | -4.07 Million AUD | -134.18% |
| 2005 | -1.74 Million AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -60.42 Million AUD | -54.28% |
| 2024 Q2 | -24.34 Million AUD | 0.0% |
| 2024 Q4 | -23.42 Million AUD | 0.0% |
| 2023 Q4 | -18.82 Million AUD | 0.0% |
| 2023 FY | -39.16 Million AUD | -29.65% |
| 2023 Q2 | -20.41 Million AUD | 0.0% |
| 2022 FY | -30.2 Million AUD | -38.36% |
| 2022 Q4 | -17.75 Million AUD | 0.0% |
| 2022 Q2 | -12.56 Million AUD | 0.0% |
| 2021 FY | -21.83 Million AUD | -125.04% |
| 2021 Q2 | -7.84 Million AUD | 0.0% |
| 2021 Q4 | -10.91 Million AUD | 0.0% |
| 2020 Q4 | -5.09 Million AUD | 0.0% |
| 2020 FY | -9.7 Million AUD | -36.61% |
| 2020 Q2 | -4.6 Million AUD | 0.0% |
| 2019 Q4 | -3.2 Million AUD | 0.0% |
| 2019 FY | -7.1 Million AUD | 27.29% |
| 2019 Q2 | -3.89 Million AUD | 0.0% |
| 2018 Q2 | -5.76 Million AUD | 0.0% |
| 2018 FY | -9.76 Million AUD | -129.75% |
| 2018 Q4 | -3.95 Million AUD | 0.0% |
| 2017 Q4 | -3.75 Million AUD | 0.0% |
| 2017 FY | -4.25 Million AUD | 28.56% |
| 2017 Q2 | -497.46 Thousand AUD | 0.0% |
| 2016 Q2 | -2.9 Million AUD | 0.0% |
| 2016 FY | -5.95 Million AUD | -18.23% |
| 2016 Q4 | -3.31 Million AUD | 0.0% |
| 2015 Q2 | -2.14 Million AUD | 0.0% |
| 2015 FY | -5.03 Million AUD | 2.0% |
| 2015 Q4 | -2.88 Million AUD | 0.0% |
| 2014 Q2 | -2.19 Million AUD | 0.0% |
| 2014 Q4 | -2.93 Million AUD | 0.0% |
| 2014 FY | -5.13 Million AUD | 15.86% |
| 2013 Q3 | -1.52 Million AUD | 50.34% |
| 2013 Q2 | -3.07 Million AUD | -202.3% |
| 2013 Q1 | -1.01 Million AUD | 0.0% |
| 2013 FY | -6.1 Million AUD | -50.13% |
| 2013 Q4 | -2.31 Million AUD | -52.0% |
| 2012 Q4 | -1.01 Million AUD | 0.0% |
| 2012 Q2 | -1.01 Million AUD | -9.37% |
| 2012 Q3 | -1.01 Million AUD | 0.0% |
| 2012 FY | -4.06 Million AUD | -9.37% |
| 2012 Q1 | -929.42 Thousand AUD | 0.0% |
| 2011 FY | -3.71 Million AUD | 20.3% |
| 2011 Q2 | -929.42 Thousand AUD | 20.3% |
| 2011 Q3 | -929.42 Thousand AUD | 0.0% |
| 2011 Q4 | -929.42 Thousand AUD | 0.0% |
| 2011 Q1 | -1.16 Million AUD | 0.0% |
| 2010 Q1 | -925.64 Thousand AUD | 0.0% |
| 2010 FY | -4.66 Million AUD | -25.98% |
| 2010 Q4 | -1.16 Million AUD | 0.0% |
| 2010 Q2 | -1.16 Million AUD | -25.98% |
| 2010 Q3 | -1.16 Million AUD | 0.0% |
| 2009 Q1 | -1.39 Million AUD | 0.0% |
| 2009 Q2 | -925.64 Thousand AUD | 33.57% |
| 2009 Q3 | -925.64 Thousand AUD | 0.0% |
| 2009 FY | -3.7 Million AUD | 33.57% |
| 2009 Q4 | -925.64 Thousand AUD | 0.0% |
| 2008 Q4 | -1.39 Million AUD | 0.0% |
| 2008 FY | -5.57 Million AUD | -18.7% |
| 2008 Q1 | -1.17 Million AUD | 0.0% |
| 2008 Q2 | -1.39 Million AUD | -18.7% |
| 2008 Q3 | -1.39 Million AUD | 0.0% |
| 2007 Q3 | -1.17 Million AUD | 0.0% |
| 2007 FY | -4.69 Million AUD | -15.18% |
| 2007 Q4 | -1.17 Million AUD | 0.0% |
| 2007 Q2 | -1.17 Million AUD | -15.18% |
| 2007 Q1 | -1.01 Million AUD | 0.0% |
| 2006 Q4 | -1.01 Million AUD | 0.0% |
| 2006 Q2 | -1.01 Million AUD | -140.01% |
| 2006 Q3 | -1.01 Million AUD | 0.0% |
| 2006 FY | -4.07 Million AUD | -134.18% |
| 2006 Q1 | -424.65 Thousand AUD | 0.0% |
| 2005 Q3 | -424.65 Thousand AUD | 0.0% |
| 2005 Q2 | -424.65 Thousand AUD | 0.0% |
| 2005 FY | -1.74 Million AUD | 0.0% |
| 2005 Q4 | -424.65 Thousand AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | -638.507% |
| Acrux Limited | -9.83 Million AUD | -295.131% |
| Amplia Therapeutics Limited | -4.42 Million AUD | -778.135% |
| Biome Australia Limited | -1.91 Million AUD | -1930.965% |
| BTC Health Limited | 1.05 Million AUD | 3782.148% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | -215.664% |
| CSL Limited | 5.64 Billion AUD | 100.688% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 13.266% |
| Clinuvel Pharmaceuticals Limited | 49.14 Million AUD | 179.061% |
| Noxopharm Limited | -7.53 Million AUD | -415.69% |
| PharmAust Limited | -6.65 Million AUD | -483.562% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | -437.329% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -440.704% |
| Race Oncology Limited | -13.38 Million AUD | -190.401% |
| Starpharma Holdings Limited | -15.15 Million AUD | -156.331% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | 499.907% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | -164.337% |
| Memphasys Limited | -2.7 Million AUD | -1337.028% |
| Nyrada Inc. | -4.56 Million AUD | -752.07% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -2563.046% |
| Telix Pharmaceuticals Limited | - AUD | Infinity% |
| Bio-Gene Technology Limited | -3.06 Million AUD | -1168.823% |
| Zelira Therapeutics Limited | -5.93 Million AUD | -554.357% |
| Patrys Limited | -3.53 Million AUD | -997.925% |
| Dimerix Limited | -25.05 Million AUD | -55.058% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 117.196% |
| Orthocell Limited | -11.68 Million AUD | -232.65% |
| Imugene Limited | -140.93 Million AUD | 72.428% |
| Cynata Therapeutics Limited | -8.8 Million AUD | -341.162% |
| Immutep Limited | -44.93 Million AUD | 13.53% |
| Arovella Therapeutics Limited | -7.19 Million AUD | -440.205% |
| Alterity Therapeutics Limited | -19.6 Million AUD | -98.234% |
| Nanollose Limited | -1.24 Million AUD | -3009.013% |
| Invex Therapeutics Ltd | -2.13 Million AUD | -1721.182% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | -1789.428% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | -1252.129% |
| Biotron Limited | -5.15 Million AUD | -654.338% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 17.693% |
| Tissue Repair Ltd | -4.87 Million AUD | -696.916% |
| AnteoTech Limited | -11.72 Million AUD | -231.36% |
| Hexima Limited | -1 Million AUD | -3752.017% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 40.323% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | -76.213% |
| Avecho Biotechnology Limited | -4.58 Million AUD | -746.712% |
| Actinogen Medical Limited | -12.83 Million AUD | -202.65% |
| Immuron Limited | -5.8 Million AUD | -569.823% |
| Argenica Therapeutics Limited | -5.67 Million AUD | -585.167% |